[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"non-neoplastic-hematopoietic-and-lymphoid-cell-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:non-neoplastic-hematopoietic-and-lymphoid-cell-disorder":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100538832","clonal-hematopoiesis-and-therapy-emergent-myeloid-neoplasms-in-patients-with-cancers-chances-study-100538832",false,"NCT06295965","Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study","Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers (CHANCES)","Inclusion Criteria:\n\n* Subjects who have or have had ovarian, peritoneal, or fallopian tube carcinoma who have a life expectancy of greater than 6 months and:\n\n  * Have completed or plan to complete at least 5 cycles of platinum-based chemotherapy\n\nOR\n\n* Subjects who have or have had a solid tumor diagnosis and any of the following:\n\n  * At least 4 months of exposure to a PARP inhibitor\n  * Diagnosis of a blood disorder including, but not limited to, clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or therapy-related myeloid neoplasm\n\nExclusion Criteria:\n\n* Individuals with a life expectancy of less than 6 months","ALL",{"count":18,"type":19},2000,"ESTIMATED","OBSERVATIONAL","This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is\u002Fare a genetic\u002Fenvironmental component(s) to developing blood cancer.",[23,24,25,26,27,28,29,30,31,32],"Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma","Recurrent Malignant Solid Neoplasm","Clonal Cytopenia of Undetermined Significance","Clonal Hematopoiesis","Idiopathic Cytopenia of Undetermined Significance","Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder","Ovarian Carcinoma","Myeloid Neoplasm Post Cytotoxic Therapy","RECRUITING","2026-04-14",{"date":36,"type":37},"2026-04-17","ACTUAL",{"date":39,"type":37},"2024-01-02",{"date":41,"type":19},"2031-12-31",{"name":43,"class":44},"University of Washington","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":45},"100361024","phase-2-donor-stem-cell-transplant-with-treosulfan-fludarabine-and-thiotepa-in-treating-patients-with-non-malignant-disorders-100361024","NCT03980769","Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders","Allogeneic Hematopoietic Cell Transplantation for Patients With Non-Malignant Disorders Using Treosulfan, Fludarabine, and Thiotepa","Inclusion Criteria:\n\n* Patient with nonmalignant disease treatable by allogeneic HCT\n* Patient with a nonmalignant disease that is not clearly defined (a patient with a non-malignant disease for whom genetic testing has been done and a genetic mutation responsible for their non-malignant disease phenotype has not been identified) are eligible for the study following discussion with and approval by the protocol principal investigator (PI) (Dr. Lauri Burroughs)\n* Age \\\u003C 50 years\n* DONOR: Human leukocyte antigen (HLA)-identical related donor OR unrelated donor matched for HLA-A, B, C, DRB1 and DQB1 or mismatched for a single allele at HLA-A, B, C, or a single DQB1 antigen or allele mismatch by high resolution deoxyribonucleic acid (DNA) typing\n* DONOR: Bone marrow is the preferred cell source (when feasible). However, peripheral blood stem cells (PBSC) is also allowed and the PI may determine if PBSC is preferred for certain patients\n\n  * The recommended total nucleated cell count (TNC) for bone marrow grafts is \\>= 4.0 x 10\\^8 TNC\u002Fkg (actual recipient weight)\n  * The recommended CD34 cell count for PBSC grafts is \\>= 5 x 10\\^6 CD34\u002Fkg (actual recipient weight) and the recommended maximum CD34 cell count for PBSC grafts is 10 x 10\\^6 CD34\u002Fkg (actual recipient weight)\n* DONOR: HLA-matched sibling bone marrow in combination with HLA-matched sibling umbilical cord blood if the HLA-matched sibling umbilical cord blood was collected and stored. The HLA-matched sibling bone marrow and cord blood would be matched for HLA-A, B, C, DRB1 and DQB1\n\nExclusion Criteria:\n\n* Patients with idiopathic aplastic anemia and Fanconi anemia; patients with aplastic anemia associated with paroxysmal nocturnal hemoglobinuria (PNH) or inherited marrow failure syndromes (except Fanconi anemia) will be allowed\n* Impaired cardiac function as evidenced by ejection fraction \\\u003C 35% (or, if unable to obtain ejection fraction, shortening fraction of \\\u003C 26%) or cardiac insufficiency requiring treatment or symptomatic coronary artery disease. Patients with a shortening fraction of \\\u003C 26% may be enrolled if approved by a cardiologist\n* Impaired pulmonary function as evidenced by carbon monoxide diffusing capability (DLCO) corrected \\\u003C 50% of predicted (or, if unable to perform pulmonary function tests, then oxygen \\[O2\\] saturation \\\u003C 92% on room air)\n* Impaired renal function as evidenced by:\n\n  * Estimated creatinine clearance \\\u003C 60 mL\u002Fmin\u002F1.73m\\^2 using either the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) equation for adult patients (\\>= 18 years old), or the updated Schwartz formula for pediatric patients (\\\u003C 18 years old). If the estimated creatinine clearance is \\\u003C 60 mL\u002Fmin\u002F1.73m\\^2, then renal function must be measured by 24-hour creatinine clearance, Iothalamate, Iohexol or nuclear GFR and the patient is excluded if their measured creatinine clearance is \\\u003C 50 mL\u002Fmin\u002F1.73 m\\^2, OR\n  * Serum creatinine \\> 2 x upper limit of normal, OR\n  * Dialysis dependent\n* Evidence of synthetic dysfunction or severe cirrhosis requiring deferral of conditioning as recommended by a gastroenterology specialist\n* Active infectious disease requiring deferral of conditioning as recommended by an infectious disease specialist\n* Positive for HIV (human immunodeficiency virus)\n* Females who are pregnant or breast-feeding\n* Known hypersensitivity to treosulfan, fludarabine, and\u002For thiotepa\n* DONOR: Donors deemed unable to undergo marrow harvesting of PBSC mobilization and leukapheresis\n* DONOR: HIV-positive donors\n* DONOR: Donors with active infectious hepatitis\n* DONOR: Female donor with positive pregnancy test\n* DONOR: Donors are excluded if the patient has an identified antibody against a donor-specific HLA locus as specified in standard practice\n* DONOR: HLA-matched sibling cord blood units that have not passed donor screening for infectious disease markers as recommended by the National Marrow Donor Project (NMDP) will not be used unless a waiver is signed by the clinical attending allowing use of cord blood unit. Cord blood units are presumed to be cytomegalovirus (CMV) negative regardless of serologic testing due to passive transmission of maternal CMV antibodies","50 Years",{"count":55,"type":19},40,"INTERVENTIONAL",[58],"PHASE2","This phase II clinical trial studies how well treosulfan, thiotepa, fludarabine, and rabbit anti-thymocyte globulin (rATG) before donor stem cell transplantation works in treating patients with nonmalignant (non-cancerous) diseases. Hematopoietic cell transplantation has been shown to be curative for many patients with nonmalignant (non-cancerous) diseases such as primary immunodeficiency disorders, immune dysregulatory disorders, hemophagocytic lymphohistiocytosis, bone marrow failure syndromes, and hemoglobinopathies. Powerful chemotherapy drugs are often used to condition the patient before infusion of the new healthy donor cells. The purpose of the conditioning therapy is to destroy the patient's abnormal bone marrow which doesn't work properly in order to make way for the new healthy donor cells which functions normally. Although effective in curing the patient's disease, many hematopoietic cell transplantation regimens use intensive chemotherapy which can be quite toxic, have significant side effects, and can potentially be life-threatening. Investigators are investigating whether a new conditioning regimen that uses less intensive drugs (treosulfan, thiotepa, and fludarabine phosphate) results in new blood-forming cells (engraftment) of the new donor cells without increased toxicities in patients with nonmalignant (non-cancerous) diseases.",[30],"2026-03-10",{"date":63,"type":37},"2026-03-12",{"date":65,"type":37},"2021-05-05",{"date":67,"type":19},"2028-07-01",{"name":69,"class":44},"Fred Hutchinson Cancer Center"]